Ibrutinib drug is used in all except:: (A) Mantle cell lymphoma, (B) Chronic lymphocytic leukemia, (C) Waldenstrom's macroglobulinemia, (D) AML
Answer is D. Bruton tyrosine kinase (BTK) is a validated target for B cell malignancies. BTK inhibitor ibrutinib was approved in: - Chronic lymphocytic leukaemia- Mantle cell lymphoma- Waldenstrom's macroglobulinemia NIB -drug ending with NIB are kinase inhibitor BRUT - Bruton's tyrosine kinase inhibitor